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Abstract
Genome sequences are available for 3 human-infecting malaria parasites, Plasmodium falciparum, 
P. vivax and P. knowlesi, and population genomics data are available for many endemic regions. 
This review summarizes how genomic data have been used to develop new, species-specific 
molecular targets for better malaria diagnosis. The combination of bioinformatics and genomics 
has been used to identify new sequence targets suitable for diagnostic applications and assess their 
viability within the context of global Plasmodium sequence variation. The selection criteria 
maximized the sensitivity and specificity of the novel targets. At least one target from each species 
was found to be suitable for molecular diagnosis of malaria with some advantages over existing 
molecular methods. The promise of using genome sequence data to develop sensitive, genus- or 
species-specific diagnostic methods for other pathogens of public health interest is strong. This 
undertaking together with what we envision as the future of malaria diagnosis in the ‘omic’ era is 
discussed
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Introduction
Advances in sequencing technology have led to an explosion of sequence generation, 
especially for infectious agents. As a result, genome sequences for many eukaryotic and 
prokaryotic pathogens have been generated and are publicly available. For example, the 
NCBI Genome Project database (http://www.ncbi.nlm.nih.gov/genome) provides access to 
complete genomes of a myriad of human pathogens. The almost-exponential availability of 
pathogen genome sequences has been made possible by major technological advances, or 
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‘next-generation’ DNA sequencing techniques, which have dramatically reduced the cost 
and time required to generate sequence data [1].
The genome sequence for the most lethal human malaria parasite Plasmodium falciparum 
(∼23 Mb) was first published in 2002 [2] based on the laboratory-adapted parasite isolate 
3D7. However, thousands of global Plasmodium strains and clinical isolates have since been 
examined for single nucleotide polymorphisms (SNPs) or sequenced to generate a map of 
global variation and identify and track changes related to major phenotypes such as drug 
resistance [7, 8]. The nuclear genome sequences for the human-infecting P. vivax (∼27 Mb) 
and zoonotic P. knowlesi (∼24 Mb) are also known [3, 4], and all available genome 
sequences can be easily accessed at (http://PlasmoDB.org) [5] (along with other genome-
wide datasets, such as SNPs, expression data, proteomics, etc). PlasmoDB provides tools to 
make comparisons between emerging high-throughput data sets for these organisms.
Now, more than ever, the role of genomics in understanding Plasmodium parasite biology is 
evident [6]. It is hoped that the availability of Plasmodium genome sequences will 
revolutionize the discovery of new drug targets, development of new vaccine targets and 
drug-resistant markers, and lead to improvement in other tools for fighting and controlling 
malaria such as diagnostics. Recently, genome-based association studies have contributed to 
identification of genomic regions associated with drug resistance [7, 8]. The significance of 
genomic data for understanding parasite biology, pathogenesis, drug resistance, and 
population structure has been extensively reviewed recently [9]. The scope of the current 
review is to highlight how genomics is contributing to the immediate public health needs of 
malaria diagnosis.
The molecular biologist's toolbox has improved tremendously since the advent of the 
polymerase chain reaction (PCR) in the mid-1980s. PCR-based assays are fairly standard in 
most laboratories and can be used for disease detection, forensics and drug-resistance 
surveillance testing. While several other disease-detection methods exist, molecular tools are 
still the most specific and sensitive tools. Molecular diagnostic techniques rely on in-depth 
knowledge of the target sequence and its global variability. Therefore, molecular diagnostic 
tools benefit tremendously from the increased availability of pathogen genome sequences. 
For example, genome sequences can be mined to discover conserved sequence regions 
suitable for the design of specific primers that do not cross-react with either the host or other 
species of the same genus. Likewise, highly variable regions can be avoided when designing 
detection assays, as these would lead to false negative results. Sequences which exist in high 
copy numbers can be used to design a more sensitive assay compared to assays utilizing 
single- or low-copy number sequence targets.
Why New Tools for Malaria Diagnosis?
Malaria continues to be a major global public health challenge. There were approximately 
225 million cases of malaria in 2009 with an estimated 718,000 deaths reported [10]. Five 
different Plasmodium species with different clinical implications infect humans in different 
combinations around the world. There is a renewed, concerted, international effort to fight 
and eliminate malaria through funding from the Global Fund, the U.S. Presidents Malaria 
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Initiative, the Bill and Melinda Gates Foundation and other private and public sources. Thus, 
new diagnostic assays and tools that are robust enough to accurately detect the species of 
infecting parasite(s), for case management, detection of transmission foci of malaria 
reservoirs (sub-microscopic infections) and for monitoring the success of malaria control 
and elimination programs are needed.
Existing tools for malaria diagnosis include microscopy, parasite antigen/enzyme detection 
kits (commonly referred to as rapid diagnostic tests (RDTs)) and molecular tools, which are 
mostly restricted to reference laboratories (reviewed in [11]). Microscopy remains the gold 
standard when a suitable infrastructure is available. This is the cheapest method and can 
differentiate species of malaria parasites and provide quantitative data on the level of 
parasitemia. One limitation of microscopy is that it can fail to identify mixed infections 
and/or low levels of parasitemia. Microscopic detection limits range from 50–100 
parasites/μL, depending on the level of expertise of the microscopist and other factors 
(reviewed in [11]). As malaria often occurs in communities where even microscopic 
diagnosis is not easily available, RDTs are an alternative diagnostic tool. Current RDTs 
capture products such as the histidine-rich protein −2 (Pf HRP-2), which is P. falciparum-
specific, or the ldolase and lactate dehydrogenase enzyme (LDH) which are genus-specific 
and are therefore capable of detecting all Plasmodia, but are not able to discriminate species. 
However, highly divergent species such as P. ovale can produce negative RDT results due to 
sequence variation [12]. In addition, the lack of the hrp-2 gene in some P. falciparum 
parasites in parts of South America and Africa [13, 14] has raised some concerns about 
HRP-2-based RDT use due to the potential for false negative results. Proteomics data 
generated from multiple strains can be used to develop new-generation RDTs utilizing 
multiple protein targets to overcome existing challenges.
Nucleic acid-based techniques such as PCR have revolutionized pathogen detection and 
identification, by offering high sensitivity and specificity. Molecular diagnostic methods for 
malaria diagnosis have at least 2 advantages compared to the other methods: they can 
accurately define the species of malaria parasite(s), and they can detect parasite densities 
that are well below microscopy limits. Previously, the field of malaria diagnosis was 
wrapped in debates as to what tool is clinically relevant for diagnosis and treatment of 
malaria, especially in highly endemic regions; this stemmed from the fact that molecular 
tools are very sensitive in detecting submicroscopic infections which often do not translate 
to clinical manifestations (subclinical). Others argued that molecular tests may detect 
‘lingering’ parasite DNA as opposed to active infections and may therefore not be 
appropriate assays to use. However, the malaria elimination era makes it paramount that 
even the ‘last parasite’ is found. In addition, recent studies have clearly demonstrated that 
submicroscopic gametocyte carriers (who can only be detected molecularly) are capable of 
transmitting malaria [15]. Molecular tools are thus appealing for use in both case 
management and programmatic operations, such as monitoring and evaluation of control 
programs. Molecular diagnostic tools have helped to identify zoonotic transmission of P. 
knowlesi in parts of Southeast Asia [16]. These infections were previously diagnosed as P. 
malariae or P. falciparum by microscopy. Molecular tools are also helping to identify new 
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species of malaria parasites including P. falciparum-like parasite species in non-human 
primates [17].
Evolution of Molecular Tools for Malaria Diagnostics
Several molecular diagnostic tools for malaria are available, the majority of which are PCR-
based assays. Recent technologies have led to the development of other amplification tools, 
such as loop-mediated isothermal amplification assays, that are simpler and more field-
adaptable [18, 19]. Molecular diagnosis of malaria parasites began with the use of the 18S 
ribosomal RNA (18S rRNA) gene as the target about 20 years ago [20], and this method is 
widely used in many reference laboratories with various modifications. This target was a 
logical choice in the pre-genomics era. Its regions of conserved sequence allowed cloning 
from multiple Plasmodium species facilitating the subsequent design of species-specific 
primers. Also, all eukaryotic organisms that had been examined to that date contained 
multiple, often hundreds of identical copies of 18S rRNA [21], so it seemed likely that this 
target would lead to a very sensitive assay. Plasmodium genome sequences have 
subsequently revealed that the 18S rRNA target is present in 4–8 divergent copies, 
depending upon the species [2, 3]. PCR's sensitivity is greatly influenced by the starting 
target molecule copy number; a low target copy number within the parasite limits the 
detection capabilities of these assays, especially when the parasitemia is low. Previous 
multiplex assays for simultaneous detection of malaria parasite species showed decreased 
sensitivity, particularly in detecting the minor species [22]. The 18S rRNA gene target 
presents challenges for effective multiplex platforms which would cut back on costs, test 
time and reduce contamination possibilities resulting from many primers competing for the 
same target.
Use of Genomics and Bioinformatics to Improve Malaria Diagnostic Assays
The new era of genomics and sequence availability can be harnessed to improve molecular 
diagnostic tools for malaria. Recently, we developed a bioinformatics approach to identify 
new sequence targets that are suitable for diagnostic applications (fig. 1) in P. falciparum, P. 
vivax and P. knowlesi. Ideal targets will be species-specific, present in many, well-conserved 
copies (ensuring high sensitivity) and amenable to PCR or other nucleic acid amplification 
techniques. Our semi-automated bioinformatics pipeline employed a number of screens to 
ensure candidate targets met these criteria [23, 24].
Our candidate target selection process began by accessing genome sequence data for P. 
falciparum (strain 3D7), P. vivax (strain Sal-1) and P. knowlesi (strain H) from PlasmoDB. 
Each genome was mined for repetitive sequence content, and a consensus repeat sequence 
(CRS) for each repeat family was generated. We screened and eliminated all CRSs with 
significant similarity to human sequences, significant similarity to artificial sequences that 
may have been introduced during genome sequencing and those containing internal tandem 
repeats that could potentially interfere with PCR amplification and similarity to sequences 
from other Plasmodium spp. Only species-specific CRSs that did not exhibit high levels of 
polymorphism in existing SNP data sets were considered further. We also eliminated 
candidates <300 bp to allow for primer design and evaluation of target conservation. Repeat 
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families with at least six copies were considered for further testing, yielding a total of 21 P. 
falciparum, 68 P. vivax and 19 P. knowlesi candidates.
Six P. falciparum, seven P. vivax and four P. knowlesi putative targets were selected for 
further validation. Over 64 primer pairs were designed to these targets and empirically tested 
in conventional PCR amplification assays and multiplex assays (for P. falciparum and P. 
vivax). At least one putative target from each species (summarized in table 1) was found to 
significantly improve existing diagnostic capabilities: candidates Pfr364 (P. falciparum), 
Pvr47 [23] and Pvr64 (P. vivax; designed for loop mediated isothermal amplification assays, 
[33]), and Pkrl40 (P. knowlesi) [24].
Validation of PCR Primers from Novel Targets
All primers designed to the four novel targets were shown to correctly amplify the gene of 
interest with high specificity and sensitivity (table 1). In addition, the limits of detection of 
these assays were improved. Of interest is the novel primer set for detection of P. knowlesi 
which exhibits stage-dependent morphological similarities to P. malariae and P. falciparum 
[16]. The commonly used molecular assay for the detection of P. knowlesi infection was 
recently noted to cross-react with P. vivax, leading to potential false positive results for a 
small proportion of human clinical P. vivax samples [25] and other simian Plasmodium 
species [24]. Primers designed to the Pkr 140 target consistently identified P. knowlesi 
without cross-reacting with other human malaria parasites and five other primate 
Plasmodium parasites (P. simiovale, P. cynomolgi, P. inui, P. coatneyi, and P. hylobati).
Genomic data mining allowed us to develop sensitive and highly specific PCR tests for three 
Plasmodium species. Similar approaches can be used for the other human-infecting species 
as data are available. The newly developed tests highlighted here need further validation in 
the field, and their performance can be improved by modifying reaction parameters as 
needed.
Limitations of the Described Approach
What we have described above is only an example of how genome data can be exploited for 
developing new diagnostic methods. The genome search methodology we have developed 
can be further modified depending upon the specific needs of the tools being considered for 
development. The use of a single strain to select a candidate sequence as described here is a 
limitation that can be improved. To ascertain that the designed primers are capable of 
interspecies detection, one could test the novel primers against different strains from across 
the world, as was previously done by Demas et al. [23]. However, as additional SNP and 
population variation data become freely accessible via PlasmoDB and other resources such 
as MalariaGen (Genomic Epidemiology Network), these databases can be used to determine 
sequence variation in much greater detail and aid the design of novel primers capable of 
detecting field isolates.
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The current ‘omic’ era greatly complements the growing number of new-generation tests 
and platforms for molecular diagnostic tests observed today. Recently, a microfluidic 
technology-based TaqMan low-density array (Life Technologies, Carlsbad, Calif, USA) 
card for real-time PCR detection of 21 different respiratory pathogens was described [26]. 
Such array formats can be adapted for detection of multiple malaria parasite species and can 
be integrated with detection of other pathogens of relevance. Further development of less-
expensive, simple, field-usable DNA microarrays for malaria detection will be useful for 
large-scale surveillance programs. Several isothermal amplification assays have been 
described, e.g. the SAMBA HIV-1 test for the rapid visual detection of HIV-1 by a dipstick 
[27], loop-mediated isothermal amplification [19] and its modification for real-time 
detection using portable devices [28]. Mens et al. [29] recently developed a direct-blood 
PCR assay visualized by nucleic acid lateral flow immune-assay capable of detecting 
Plasmodium; this assay attempts to circumvent the DNA isolation step, a major hurdle 
towards the simplification of molecular tests. The current direction is towards simple, robust 
and cheap tests that can detect multiple disease agents and hopefully enable their use in 
point-of-care settings with limited resources.
Use of Proteomics to Improve Malaria Antigen-Based RDTs
The next-generation RDTs will require a better selection of Plasmodium antigens that are 
highly abundant, highly conserved across geographic regions and species-specific. The use 
of genomics and bioinformatics is not limited to the development of molecular assays; these 
tools together with proteomics can be used to select for Plasmodium antigens that meet these 
standards. In an effort to improve the current malaria RDTs, Kattenberg et al. [30] recently 
tested monoclonal antibodies against three Plasmodium antigens: glutamate-rich protein, 
dihydrofolate reductase-thymidylate synthase and heme detoxification protein for their 
potential use in RDTs. This study highlights the feasibility of developing next-generation 
RDTs with multiple protein targets that could be identified and validated using proteomics 
data.
Molecular Barcodingfor Differentiating Parasite Populations and Their Use in Outbreak 
and Elimination Programs
In outbreak investigations and during post-elimination monitoring of malaria, it will be 
important to identify the geographic source of malaria parasites. Recently, a molecular 
barcode study using 24 SNPs from the P. falciparum genome was developed and tested for 
its utility in differentiating parasite populations [31]. Further validation and improvement of 
such molecular barcodes and curation of publicly shared databases housing these data will 
be invaluable for public health investigations and tracking of drug-resistant parasite 
populations. Using multi-locus genotyping of microsatellite markers, it has been shown that 
recent Peruvian P. falciparum populations have evolved from five clonal lineages in the 
post-malaria eradication era [32], demonstrating the utility of genomic data in facilitating the 
public health response to control and eliminate malaria.
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Availability of genome data for human malaria parasites has led to significant advances in 
understanding the biology of malaria parasites and determination of genetic targets 
associated with evolving resistance to artemisinin as well as other applications [9]. We have 
highlighted the value of generating population level genomic data, applying bioinformatics 
methods and mining these data to identify novel targets for malaria diagnosis and 
surveillance. We view these initial forays with bioinformatics as only the tip of the iceberg 
when considering the possible uses of genomic data to address a large variety of public 
health demands. Novel diagnostic tests with better sensitivity and specificity than current 
tests can be developed with advancing genomics knowledge of malaria parasites. Such tools 
will be highly relevant for malaria control programs and efficient public health response.
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Schematic of diagnostic target screening and development pipeline. Genomic sequences for 
P. falciparum (Pf), P. vivax (Pv), and P. knowlesi (Pk) were downloaded from PlasmoDB. 
Data were mined for repeats using the RepeatScout algorithm to construct consensus repeat 
sequences (CRSs) for each identified repeat family. We identified 418 CRSs for Pf, 428 
CRSs for Pv and 423 CRSs for Pk. CRSs were then screened in parallel for tandem repeats, 
similarity to human sequences and vector sequences. Pf, Pv and Pk CRSs passing these 
screens and proceeding to the next steps are indicated in parentheses. Any CRSs failing 
these screens were removed from further consideration. CRSs that were not species-specific 
or less than 300 bp long were eliminated. Family copy numbers for the remaining candidates 
were determined via comparison of the CRSs against the appropriate genome sequences. 
Candidate repeat families containing six or more copies and separated by at least 100 bp 
were considered for further testing.
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